ALNY — Alnylam Pharmaceuticals, Inc. stock price, charts and financials
QT28Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | NDX | P/E | 41.47 | EPS (ttm) | 5.92 | Insider Own | 0.27% | Shs Outstand | 133.81M | Perf Week | -0.81% |
| Market Cap | 32.85B | Forward P/E | 24.36 | EPS next Y | 10.08 | Insider Trans | -2.11% | Shs Float | 133.23M | Perf Month | 7.39% |
| Enterprise Value | 30.76B | PEG | 1.68 | EPS next Q | 1.77 | Inst Own | - | Short Float | 4.76% | Perf Quarter | -13.16% |
| Income | 807.00M | P/S | 6.84 | EPS this Y | 12.74% | Inst Trans | - | Short Ratio | 3.64 | Perf Half Y | -22.01% |
| Sales | 4.80B | P/B | 24.26 | EPS next Y | 50.99% | ROA | 14.54% | Short Interest | 6.34M | Perf YTD | -38.26% |
| Book/sh | 10.12 | P/C | 9.93 | EPS next 5Y | 24.63% | ROE | 93.61% | 52W High | 495.58 -50.46% | Perf Year | -46.77% |
| Cash/sh | 24.72 | P/FCF | 61.33 | EPS past 3/5Y | - | ROIC | 24.43% | 52W Low | 197.82 24.11% | Perf 3Y | 16.00% |
| Dividend Est. | - | EV/EBITDA | 26.75 | Sales past 3/5Y | 53.00% 49.76% | Gross Margin | 79.72% | Volatility | 3.18% 4.17% | Perf 5Y | 29.49% |
| Dividend TTM | - | EV/Sales | 6.40 | EPS Y/Y TTM | 371.56% | Oper. Margin | 20.81% | ATR (14) | 10.78 | Perf 10Y | 238.49% |
| Dividend Ex-Date | - | Quick Ratio | 2.99 | Sales Y/Y TTM | 113.70% | Profit Margin | 16.82% | RSI (14) | 49.04 | Recom | 2.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.05 | EPS Q/Q | 337.25% | SMA20 | -0.33% | Beta | 0.25 | Target Price | 347.33 |
| Payout | 0.00% | Debt/Eq | 1.56 | Sales Q/Q | 66.80% | SMA50 | -1.56% | Rel Volume | 0.52 | Prev Close | 239.36 |
| Employees | 2,500 | LT Debt/Eq | 1.56 | Earnings | Oct 29 | SMA200 | -21.62% | Avg Volume | 1.83M | Price | 245.51 |
| IPO Date | Jun 01, 2004 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -25.78% -2.36% | Net Debt/EBITDA | -0.38 | Volume | 954,012 | Change | 2.57% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-08-26 | Reiterated | Jefferies | Hold | $230 → $260 |
| Aug-28-26 | Reiterated | Jefferies | Hold | $205 → $230 |
| Aug-25-26 | Reiterated | Bernstein | Outperform | $447 → $376 |
| Aug-14-26 | Reiterated | Wells Fargo | Equal Weight | $376 → $256 |
| Aug-04-26 | Reiterated | HC Wainwright & Co. | Buy | $485 → $455 |
| Aug-04-26 | Reiterated | Truist Securities | Buy | $410 → $315 |
| Aug-03-26 | Upgrade | Raymond James | Outperform → Strong Buy | $420 |
| Aug-03-26 | Reiterated | Barclays | Overweight | $527 → $450 |
| Jul-31-26 | Reiterated | Stifel Nicolaus | Buy | $444 → $318 |
| Jul-31-26 | Reiterated | Oppenheimer | Outperform | $500 → $350 |
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,804 | 3,714 | 2,248 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 974 | 677 | 323 | — | — | — | — | — | — | |
| Gross Profit | 3,830 | 3,037 | 1,925 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,318 | 1,211 | 976 | — | — | — | — | — | — | |
| Research and Development | 1,509 | 1,324 | 1,126 | — | — | — | — | — | — | |
| Other Operating Expense | 3 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 1,000 | 502 | -177 | — | — | — | — | — | — | |
| Interest Expense | 324 | 253 | 142 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 124 | 74 | -59 | — | — | — | — | — | — | |
| Net Income Before Taxes | 800 | 323 | -377 | — | — | — | — | — | — | |
| Income Taxes | -40 | 9 | -99 | — | — | — | — | — | — | |
| Consolidated Net Income | 807 | 314 | -278 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 838 | 314 | -278 | — | — | — | — | — | — | |
| Net Income | 807 | 314 | -278 | — | — | — | — | — | — | |
| EPS (Recurring) | 6.10 | 2.39 | -2.18 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.10 | 2.39 | -2.18 | — | — | — | — | — | — | |
| EPS (Diluted) | 5.92 | 2.33 | -2.18 | — | — | — | — | — | — | |
| EBITDA | 1,150 | 631 | -179 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 41.47 | 170.67 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 6.80 | 14.03 | 13.40 | — | — | — | — | — | — | |
| Gross Margin | 79.73 | 81.77 | 85.63 | — | — | — | — | — | — | |
| Operating Margin | 20.82 | 13.52 | -7.87 | — | — | — | — | — | — | |
| Net Margin | 16.80 | 8.45 | -12.37 | — | — | — | — | — | — | |
| Shares Outstanding | 133 | 131 | 128 | — | — | — | — | — | — | |
| Market Capitalization | 32,653 | 52,092 | 30,120 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| PYOTT DAVID E I | Director | Jun 01 '26 | Sale | 299.18 | 3,830 | 1,145,852 | 1,582 | Jun 03 |
| PYOTT DAVID E I | Director | Jun 01 '26 | Option Exercise | 0.00 | 3,830 | 0 | 5,412 | Jun 03 |
| SCHULMAN AMY W | Director | May 13 '26 | Option Exercise | 70.20 | 11,250 | 789,750 | 23,211 | May 14 |
| McLaughlin Melissa | Chief Human Resources Officer | Apr 06 '26 | Sale | 330.42 | 2,286 | 755,329 | 9,443 | Apr 07 |
| McLaughlin Melissa | Chief Human Resources Officer | Apr 02 '26 | Sale | 319.59 | 1,624 | 519,014 | 11,729 | Apr 07 |
| Garg Pushkal | EVP Chief R&D | Mar 05 '26 | Sale | 323.96 | 2,404 | 778,812 | 18,693 | Mar 06 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Mar 05 '26 | Sale | 323.98 | 658 | 213,177 | 20,569 | Mar 06 |
| Garg Pushkal | EVP Chief R&D | Mar 04 '26 | Sale | 323.08 | 2,309 | 745,983 | 21,097 | Mar 06 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Mar 04 '26 | Sale | 323.08 | 633 | 204,508 | 21,227 | Mar 06 |
| Greenstreet Yvonne | Chief Executive Officer | Mar 04 '26 | Sale | 323.08 | 2,933 | 947,581 | 95,695 | Mar 06 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Mar 04 '26 | Sale | 323.08 | 2,468 | 797,349 | 61,805 | Mar 06 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Mar 04 '26 | Sale | 323.08 | 2,309 | 745,983 | 34,297 | Mar 06 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Mar 03 '26 | Sale | 319.73 | 1,652 | 528,189 | 21,860 | Mar 04 |
| Garg Pushkal | EVP Chief R&D | Mar 03 '26 | Sale | 319.74 | 1,775 | 567,547 | 23,406 | Mar 04 |
| Garg Pushkal | EVP Chief R&D | Mar 02 '26 | Sale | 327.66 | 1,717 | 562,586 | 25,181 | Mar 04 |